LifeStance Health Group, Inc. (NASDAQ:LFST) Receives Consensus Recommendation of “Moderate Buy” from Analysts

LifeStance Health Group, Inc. (NASDAQ:LFST) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $11.50.

Several equities analysts have recently commented on LFST shares. BTIG Research upped their price objective on shares of LifeStance Health Group from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, July 24th. The Goldman Sachs Group initiated coverage on shares of LifeStance Health Group in a report on Friday, June 5th. They issued a “neutral” rating and a $9.00 target price for the company. JPMorgan Chase & Co. boosted their target price on LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Barclays raised their price target on LifeStance Health Group from $9.00 to $13.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th.

LifeStance Health Group Stock Up 3.3%

Shares of LFST opened at $11.24 on Wednesday. The company’s 50-day moving average price is $9.46 and its 200 day moving average price is $7.87. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $11.76. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.18. The firm has a market cap of $4.36 billion, a P/E ratio of 187.33 and a beta of 1.12.

LifeStance Health Group (NASDAQ:LFST) last announced its earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. LifeStance Health Group had a net margin of 1.55% and a return on equity of 1.56%. The company had revenue of $403.48 million during the quarter, compared to analyst estimates of $387.46 million. The business’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, sell-side analysts forecast that LifeStance Health Group will post 0.12 earnings per share for the current year.

Insider Activity at LifeStance Health Group

In other LifeStance Health Group news, Director Robert Bessler sold 894,337 shares of LifeStance Health Group stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the transaction, the director directly owned 539,763 shares of the company’s stock, valued at $5,467,799.19. The trade was a 62.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Darren M. Black sold 5,899,661 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the sale, the director owned 23,310,115 shares in the company, valued at $186,947,122.30. This trade represents a 20.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 7,687,394 shares of company stock worth $63,579,701. 3.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Larson Financial Group LLC grew its holdings in shares of LifeStance Health Group by 19,952.6% in the fourth quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock valued at $27,000 after purchasing an additional 3,791 shares in the last quarter. KBC Group NV acquired a new stake in LifeStance Health Group during the 1st quarter worth approximately $29,000. EverSource Wealth Advisors LLC lifted its holdings in LifeStance Health Group by 359.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock worth $44,000 after buying an additional 5,404 shares in the last quarter. Bayesian Capital Management LP purchased a new position in LifeStance Health Group in the 2nd quarter valued at approximately $52,000. Finally, PNC Financial Services Group Inc. boosted its position in LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock valued at $59,000 after buying an additional 7,987 shares during the period. Hedge funds and other institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.